Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...
The Trump administration has promised vast changes to U.S. science and environmental policy—and we’re tracking them here as they happen. ByNational Geographic Staff In 2017, the arrival of the Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback